Jazz, Hikma must face 'reverse payment' claims over narcolepsy drug
By Mike Scarcella
Aug 27 (Reuters) -Drug companies Jazz JAZZ.O and Hikma HIK.L must face claims that they schemed to delay a generic version of Jazz’s blockbuster narcolepsy drug Xyrem, causing health plans to pay higher prices, a U.S. judge in California has ruled.
U.S. District Judge Richard Seeborg’s ruling on Monday night in San Francisco cleared a path to trial on some claims in the long-running multidistrict legal action. Some of the plaintiffs' claims were thrown out in the order.
The plaintiffs include Blue Cross Blue Shield Association, the city of Providence, Rhode Island, and New York State Teamsters Council Health and Hospital Fund.
They have alleged Jazz violated U.S. antitrust law through a monetary payment that kept a rival generic off the market longer than it otherwise would have been, and by dispensing Xyrem through a single specialty pharmacy.
Jazz in a statement on Tuesday said the judge's order "meaningfully" trimmed the plaintiffs' claims, and the company remained "confident about the strength of its defenses."
Hikma on Tuesday did not immediately respond to a request for comment. Both companies have denied any wrongdoing.
Attorneys for the plaintiffs at Girard Sharp and Motley Rice did not immediately respond to requests for comment.
Xyrem, a central nervous system depressant, has been on the market since 2002, when it was manufactured by Orphan Medical. Ireland-based Jazz acquired Orphan in 2005.
The plaintiffs allege Jazz, between 2007 and 2014, raised the price of Xyrem by more than 800%. In 2021, Jazz sold more than $1.8 billion of Xyrem, according to a company report.
Hikma had U.S. regulatory approval for a generic version of Xyrem by 2017. That year, Hikma settled its lawsuit challenging Jazz patents. The plaintiffs allege the accord was an unlawful “reverse payment agreement" that delayed Hikma from marketing generic Xyrem for years. Hikma’s generic entered the market last year.
Jazz has defended its marketing of Xyrem. It told the judge that a U.S. regulatory agency approved the company’s plan to distribute Xyrem through a single pharmacy. Jazz also said there are other treatments for narcolepsy.
Jazz said it had used coupons and other rebates to help keep patients’ costs for Xyrem low and in line with other narcolepsy drugs.
A status hearing in the case is scheduled for October.
The case is In Re: Xyrem (Sodium Oxybate) Antitrust Litigation, U.S. District Court, Northern District of California, No. 3:20-md-02966-RS.
Read more:
Jazz Pharma ruling clears U.S. roadblock for rival narcolepsy drug
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
